Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator

Paloma Jordà 1,2,3†, Laurens P. Bosman 4‡, Alessio Gasperetti 5, Andrea Mazzanti 6,7,8, Jean-Baptiste Gourraud 9, Brianna Davies 10, Tanja Charlotte Frederiksen 11,12, Zoraida Moreno Weidmann 13, Andrea Di Marco 14, Jason D. Roberts 15,16,17, Ciorsti MacIntyre 18, Colette Seifer 19, Antoine Delinière 20, Wael Alqarawi 21, Deni Kukavica 6,7,8, Damien Minois 9, Alessandro Trancuccio 6,7,8, Marine Arnaud 9, Mattia Targetti 22, Annamaria Martino 23, Giada Oliviero 23, Daniel C. Pipilas 24, Corrado Carbucicchio 25, Paolo Compagnucci 26, Antonio Dello Russo 26, Iacopo Olivotto 22, Leonardo Calò 23, Steven A. Lubitz 24, Michael J. Cutler 28, Philippe Chevalier 20, Elena Arbelo 2,3,29,30, Silvia Giuliana Priori 6,7,8, Jeffrey S. Healey 15,16, Hugh Calkins 5, Michela Casella 27, Henrik Kjærluf Jensen 11,12, Claudio Tondo 25,31, Rafik Tadros 1, Cynthia A. James 5, Andrew D. Krahn 10, and Julia Cadrin-Tourigny 6,1*.

1 Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, Montréal, QC, Canada; 2Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; 3Institut d’Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 4Division of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands; 5Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA; 6Department of Molecular Medicine, University of Pavia, Pavia, Italy; 7Department of Molecular Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy; 8Department of Molecular Cardiology, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; 9Department of Cardiology, Centre d’Hospitalitat Universitària Nantes, Nantes, France; 10Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia, Vancouver, BC, Canada; 11Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark; 12Department of Clinical Medicine, Health, Aarhus University, Aarhus N, Denmark; 13Department of Cardiology, Hospital de la Santa Creu i Sant Pau, IDIBAPS, Barcelona, Spain; 14Arrhythmia Unit, Department of Cardiology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain; 15Population Health Research Institute, McMaster University, Hamilton, ON, Canada; 16Division of Cardiology, Hamilton Health Sciences, Hamilton, ON, Canada; 17Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, ON, Canada; 18Cardiac Electrophysiology Service, Quenn Elisabeth II Health Sciences Center, Dalhousie University, Halifax, NS, Canada; 19St-Boniface Hospital, University of Manitoba, Winnipeg, MB, Canada; 20National Reference Center for Inherited Arrhythmias of Lyon, Louis Pradel Cardiovascular Hospital, Hospices Civils de Lyon, Lyon, France; 21Cardiac Electrophysiology Service, Ottawa Heart Institute, University of Ottawa, Ottawa, ON, Canada; 22Cardiomyopathy Unit, Department of Cardiology, Careggi University Hospital, Florence, Italy; 23Arrhythmia Unit, Department of Cardiology, Policlinico Casilino, Rome, Italy; 24Cardiovascular Research Center and Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, USA; 25Department of Clinical Electrophysiology and Cardiac Pacing Center Cardiologico Monzino, IRCCSC, Milan, Italy; 26Department of Biomedical Sciences and Public Health, Cardiology and Arrhythmology Clinic, University Hospital Umberto I-Salesi–Lancisi, Marche Politecnich University, Ancona, Italy; 27Department of Clinical, Special and Dental Sciences, Cardiology and Arrhythmology Clinic, University Hospital Umberto I-Salesi–Lancisi, Marche Politecnich University, Ancona, Italy; 28Intermountain Medical Center Heart Institute, Intermountain Medical Center, Murray, UT, USA; 29Centro di Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; 30European Reference Network for rare, low prevalence and complex diseases of the heart – ERN GUARD-Heart; and 31Department of Biomedical, Surgical and Dentistry Sciences, University of Milan, Milan, Italy

Received 17 November 2021; revised 16 April 2022; accepted 18 May 2022; online publish-ahead-of-print 29 June 2022

See the editorial comment for this article ‘Arrhythmogenic right ventricular cardiomyopathy: the never-ending quest for a risk calculator’, by Estelle Gandjbakhch and Annina S. Vischer, https://doi.org/10.1093/eurheartj/ehac324.
Abstract

Aims

Arrhythmogenic right ventricular cardiomyopathy (ARVC) causes ventricular arrhythmias (VAs) and sudden cardiac death (SCD). In 2019, a risk prediction model that estimates the 5-year risk of incident VAs in ARVC was developed (ARVCrisk.com). This study aimed to externally validate this prediction model in a large international multicentre cohort and to compare its performance with the risk factor approach recommended for implantable cardioverter-defibrillator (ICD) use by published guidelines and expert consensus.

Methods and results

In a retrospective cohort of 429 individuals from 29 centres in North America and Europe, 103 (24%) experienced sustained VA during a median follow-up of 5.02 (2.05–7.90) years following diagnosis of ARVC. External validation yielded good discrimination (C-index of 0.70 (95% confidence interval 0.65–0.75)) and calibration slope of 1.01 (95% CI 0.99–1.03). Compared with the three published consensus-based decision algorithms for ICD use in ARVC (Heart Rhythm Society consensus on arrhythmogenic cardiomyopathy, International Task Force consensus statement on the treatment of ARVC, and American Heart Association guidelines for VA and SCD), the risk calculator performed better with a superior net clinical benefit below risk threshold of 35%.

Conclusion

Using a large independent cohort of patients, this study shows that the ARVC risk model provides good prognostic information and outperforms other published decision algorithms for ICD use. These findings support the use of the model to facilitate shared decision making regarding ICD implantation in the primary prevention of SCD in ARVC.

Structured Graphical Abstract

Key Question
Does the published arrhythmogenic right ventricular cardiomyopathy (ARVC) risk calculator (ARVCrisk.com) adequately predict sustained ventricular arrhythmia (VA) in a distinct geographically diverse cohort?

Key Finding
The ARVC risk calculator:
1) Predicted adequately with good discrimination and calibration.
2) Performed better than other consensus-based implantable cardioverter-defibrillator (ICD) implantation algorithms.

Take Home Message
The ARVC risk calculator provides reliable information and can facilitate shared decision-making regarding ICD implantation in primary prevention ARVC.

Validation of the arrhythmogenic right ventricular cardiomyopathy (ARVC) risk calculator in a distinct cohort. AHA, American Heart Association; ECG, electrocardiogram; HRS, Heart Rhythm Society; ICD, implantable cardioverter-defibrillator; ITFC, International Task Force Criteria; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; VA, ventricular arrhythmia.
Introduction

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a significant cause of sustained ventricular arrhythmia (VA) and sudden cardiac death (SCD), especially in young individuals and athletes. Preventing this catastrophic outcome through the prophylactic use of implantable cardioverter-defibrillators (ICDs) is a cornerstone of the disease management. Given the significant drawbacks associated with ICDs in this young and active population, appropriate patient selection is essential.

Over the past 25 years, numerous studies have identified predictors of sustained VA and SCD in ARVC and consensus documents have integrated these in decision algorithms for ICD use.1–3 Building on this knowledge, a risk prediction model for sustained VA and SCD in ARVC was recently developed in a multinational cohort (n = 528, designed as the derivation cohort) mostly including high volume referral centres for ARVC.4 This prediction model provides individualized prediction of the risk of VA in patients with ARVC without a prior history of sustained VA. Since its online publication, the risk calculator’s official site (http://www.ARVCrisk.com) has been used ∼20 000 times illustrating its uptake in clinical practice.

The model has been internally and externally validated in small studies.5–9 However, adequately powered external validation is still lacking,10 yet is paramount to confirm the reproducibility, generalizability, and need to update the model in an independent population.

The aims of the present study are thus (i) to conduct external validation of the published risk calculator in a distinct, adequately powered, and geographically diverse cohort including patients from six countries across North America and Europe and (ii) to compare the performance of the risk prediction model with other published guidelines and expert consensus recommendations for ICD use. During the current validation study, our group detected an inaccuracy in the formula of the original ARVC risk calculator published in 2019. It was corrected both on the website (ARVCrisk.com) and in the published manuscript.11 We base the present study on the corrected risk calculator.

Methods

Study design

We conducted an observational, retrospective, longitudinal cohort study in accordance with the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement.12

Study population

The study population was derived from 29 centres (see Supplementary material online, Table S1) in six European and North American countries. This current cohort will be designated as the ‘validation cohort’ while the cohort leading to the published model will be designated as the ‘derivation cohort’. New patients from two centres participating in the original study (Montreal Heart Institute and Johns Hopkins Hospital) were included (52 patients; 12% of the cohort). No patients in the current cohort were included in the original ARVC derivation cohort. From each site, consistent with the derivation cohort, consecutive patients who (i) were diagnosed with definite ARVC as per 2010 Task Force Criteria (TFC),13 (ii) were alive at presentation, and (iii) had not experienced spontaneous sustained VA or sudden cardiac arrest (SCA) at diagnosis were included. The study conforms to the Helsinki declaration and was approved by local ethics and/or institutional review boards. To maintain patient confidentiality, data, and study materials will not be made available to other researchers for purposes of replicating the results. A limited dataset may be made available upon request.

Data collection

Data were collected independently by each of the participating centres using uniform definitions. A complete list of variables and their definitions can be found in Supplementary material online, Table S2. Genetic variants were reviewed according to the American College of Medical Genetics and Genomics guidelines by cardiologists specialized in cardiovascular genetics (R.T. and J.C.T.).14

Missing data

Patients with >50% of predictors missing were excluded from the analysis. Missingness was assumed to be at random and imputed using multiple imputation by chained equations.15 Missing quantitative values for right ventricular ejection fraction (RVEF) and left ventricular ejection fraction (LVEF) were imputed manually when only qualitative assessment was available as done previously4 and detailed in Supplementary material online, Table S2. The multiple imputation model included all pre-specified predictors, proband status and genotype together with the outcome, and cumulative baseline hazard estimation.16 A total of 25 imputed datasets were generated, and the final inference estimations were combined using Rubin’s rules.17

Study outcomes

In accordance with the published ARVC risk prediction model which this study aims to validate, the primary outcome was the first sustained VA following the definite diagnosis as per the TFC. Sustained VA was defined as a composite of the occurrence of SCD, SCA, spontaneous sustained ventricular tachycardia (VT; lasting ≥30 s at ≥100 b.p.m. or with haemodynamic compromise requiring cardioversion), ventricular fibrillation/flutter, or appropriate ICD intervention. Heart transplantation, cardiovascular mortality, and all-cause mortality were also collected.

Predictor variables and risk calculator

The same candidate predictors as those selected in the published model based on prior literature were considered.18–20 These include sex, age, recent cardiac syncope (here defined as transient loss of consciousness and postural tone with spontaneous recovery with a likely arrhythmic mechanism, within a year of diagnosis), non-sustained VT (NSVT; defined as hemodynamically stable VT at ≥100 b.p.m., for ≥3 beats <30 s), number of premature ventricular complexes (PVCs) on 24-h Holter monitoring, the extent of T-wave inversion (TWI) on anterior and inferior leads, and RVEF. Each predictor variable was determined at the time of...
Categorical variables were presented as frequencies (%) and compared in group risk, while maintaining adequate group sizes for precision. For presentation was based on the balance between providing sufficient spread of the original model using the Akaike information criterion (AIC), with a difference of 6.57.

\[ P(\text{VA at 5 years}) = 1 - 0.8396^{\text{LP}} \]

where the linear predictor (LP) was calculated according to the equation:

\[ \text{LP} = 0.488 \times \text{male sex} - 0.022 \times \text{age} + 0.657 \]

\[ \times \text{history of recent cardiac syncope} + 0.811 \times \text{history of NSVT} + 0.170 \times \ln(24\text{-h PVC count}) + 0.113 \]

\[ \times \text{sum of anterior and inferior leads with TWI} - 0.025 \]

\[ \times \text{RVEF} \]

Of note, the baseline hazard for 5-year prediction (0.8396) has been corrected since the initial publication in 2019.11

**Statistical analysis**

Analyses were performed with RStudio version 1.3.1093 (Boston, MA, USA). Continuous variables were expressed as mean ± standard deviation or median (interquartile range (IQR)), and compared using either the independent sample t-test or the Mann–Whitney U test. Categorical variables were presented as frequencies (%) and compared using the Fisher’s exact test. Follow-up duration was calculated as the time interval between the time of definite diagnosis according to TFC and the endpoint or censoring. Censoring was defined as death from any other cause, heart transplantation or the most recent follow-up visit at which the endpoint could be ascertained. Event-free survival probability was estimated using the Kaplan–Meier method and Cox proportional hazard regression analysis.

**Model validation**

The approach to external validation follows the method suggested by Royston and Altman for Cox prognostic models.25 First, the overall discriminative performance of the model was measured using Harrell’s C-statistic, and the model fit by calculating the calibration slope, the regression of the LP (i.e. the product of the variable part of the Cox model) in the current cohort (validation cohort). Graphical evaluation of calibration was performed by plotting the predicted risk against the observed risk of sustained VA, using grouped Kaplan–Meier estimates and the continuous hazard regression function. The choice of the number of groups presented was based on the balance between providing sufficient spread in group risk, while maintaining adequate group sizes for precision. For the complete cohort, five groups are presented while for subgroup analyses, four groups are presented.

Subsequently, a more in-depth analysis of the model fit was performed by a Cox’s model including the same predictor variables in combination with the LP of the original model (as an offset variable) to evaluate potential differences in the regression coefficients of each individual predictor. The result indicating the validity of the model would be that if all coefficients β equalled 0, reflecting that all the variability in the validation sample is accounted for by the published model. In addition, the baseline survival function of the validation dataset was compared to that of the derivation dataset to see if the overall predictions need to be globally shifted upward or downward. Lastly, a new prediction model using the same predictor variables was fitted to the validation dataset and compared to the fit of the original model using the Akaike information criterion (AIC), with a difference of >2 defined as statistically significant. This allows testing whether a model specifically fitted to the validation dataset performs better than the original model in the validation dataset.

**Subgroup analyses**

We visually explored the performance of the model specifically in different populations of interest by comparing calibration plots for these subgroups. We stratified the cohort by geographic origin (Europe vs. North America), by proband status and by plakophilin 2 carrier status (PKP2; causal variant carrier vs. non-carrier). We did not report quantitative markers of performance such as the C-statistic as this study was not powered adequately for these subgroups.

To assess the impact of carrying an ICD on prediction accuracy, we also presented calibration plots based on ICD carrier status at baseline defined as ICD implantation prior to a year following diagnosis and first VA outcome, whichever came first.

**Clinical utility**

To assess the relative clinical utility of the risk prediction model, it was compared to three other published expert consensus algorithms for ICD implantation in ARVC: the 2015 International Task Force Consensus for the treatment of ARVC (ITFC),18 the 2017 American Heart Association (AHA) guidelines for the management of VA and prevention of SCD,2 and the 2019 Heart Rhythm Society (HRS) consensus on arrhythmogenic cardiomyopathy (excluding programmed ventricular stimulation)23 through decision curve analysis. In a decision curve analysis,23 the clinical benefit is assessed by the ‘net benefit’ representing the balance between useful (i.e. in patients with events) vs. useless (i.e. in patients without events) ICD placement at 5 years weighted according to the threshold used for ICD implantation. More specifically, the decision curve uses the following formula:

\[ \text{True positives/total sample size} - \text{false positives/total sample size} \times (\text{pt}/1 - \text{pt}) \]

where ‘pt’ represents threshold probability, in the current case, threshold for ICD implantation. Therefore, the higher the threshold used, the greater the harm of useless ICD use (i.e. false positive) is valued. Higher values indicate greater benefit while a value of 0 indicates no benefit.

To present the consequence of setting different thresholds for ICD implantation, we evaluated and plotted the proportion of patients who would receive ICDs and the proportion of treated and missed events at each threshold. We compared these with the recommendations for ICD use by the three published consensus mentioned above [ITFC(1), AHA (2), HRS(3)].

**Results**

The study population included 429 definite ARVC patients without a history of sustained VA or SCA at the time of diagnosis aged 43.1 ± 15.8 years and slightly more than half (n = 235, 54.8%) were male. Probands accounted for two-thirds of the cohort (n = 278, 64.8%). Half (n = 198, 46.6%) of patients had a pathogenic or likely pathogenic variant in a gene with definite or moderate association with ARVC,24 which represents 70% (198 patients) of the 282 patients for whom the complete genetic information was available. PKP2 was the most common genotype, carried by 111 patients (26%) followed by DSP in 38 patients (9%). Compared to PKP2 patients, DSP patients were more likely to have a decrease in LVEF <
50% (44.7% vs. 6.4%) but less likely to have VA events at follow-up (13.2% vs. 24.5%). Baseline characteristics according to genotype are presented in Supplementary material online, Table S3. Other clinical and demographic characteristics are summarized in Table 1. Baseline characteristics by country of origin are presented in Supplementary material online, Table S4, and a comparison of the derivation and validation cohort populations is presented in Supplementary material online, Table S5.

Overall, 299 (70.0%) patients had complete data for the pre-specified predictors. Six of the eight predictors had missing data:

### Table 1 Baseline clinical characteristics

| Demographics and genetics | Overall (n = 429) | Non-sustained VA (n = 326) | Sustained VA (n = 103) | P-value |
|---------------------------|-------------------|----------------------------|------------------------|---------|
| Age at diagnosis (years)  | 43.1 ± 15.8       | 44.1 ± 15.7                | 40.1 ± 16.0            | 0.025   |
| Male sex                  | 235 (54.8)        | 159 (48.8)                 | 76 (73.8)              | <0.001  |
| Proband status            | 278 (64.8)        | 197 (60.4)                 | 81 (78.6)              | 0.001   |
| (Likely) pathogenic variants (n = 282) | 198 (46.2) | 150 (46.0) | 48 (46.6) | 0.480   |

| Genotype                  |                   |                           |                        | 0.302   |
|---------------------------|-------------------|----------------------------|------------------------|---------|
| PKP2                      | 111 (25.6)        | 84 (25.8)                  | 27 (26.2)              |         |
| DSP                       | 38 (8.9)          | 33 (10.1)                  | 5 (4.9)                |         |
| DSG2                      | 27 (6.3)          | 22 (6.7)                   | 5 (4.9)                |         |
| DSC2                      | 3 (0.7)           | 1 (0.3)                    | 2 (1.9)                |         |
| JUP                       | 0 (0.0)           | 0 (0.0)                    | 0 (0.0)                |         |
| TMEM43                    | 10 (2.3)          | 4 (1.2)                    | 6 (5.8)                |         |
| PLN                       | 3 (0.7)           | 3 (0.9)                    | 0 (0.0)                |         |
| Multiple mutations        | 6 (1.4)           | 3 (0.9)                    | 3 (2.9)                |         |

| Clinical history          |                   |                           |                        |         |
|---------------------------|-------------------|----------------------------|------------------------|---------|
| Recent cardiac syncpe     | 37 (8.6)          | 16 (4.9)                   | 21 (20.4)              | <0.001  |

| ECG/continuous ECG monitoring | Overall (n = 424) | Non-sustained VA (n = 326) | Sustained VA (n = 103) | P-value |
|-------------------------------|-------------------|----------------------------|------------------------|---------|
| TWI in ≥3 precordial leads    | 250 (58.3)        | 187 (57.4)                 | 63 (61.2)              | 0.295   |
| TWI in ≥2 inferior leads      | 109 (25.4)        | 81 (24.8)                  | 28 (27.2)              | 0.589   |
| PVC count (n = 324)           | 1434 (439–3601)   | 1354 (400–3719)            | 1676 (602–3492)        | 0.160   |
| NSVT (n = 359)                | 148 (34.5)        | 105 (32.2)                 | 43 (41.7)              | 0.001   |

| Imaging                     |                   |                           |                        |         |
|-----------------------------|-------------------|----------------------------|------------------------|---------|
| RVEF (%) (n = 410)          | 45 (36–53)        | 47 (38–53)                 | 40 (35–48.5)           | <0.001  |
| LVEF (%) (n = 404)          | 57 (51–60)        | 57 (51–61)                 | 57 (50–60)             | 0.049   |

| Treatment at baseline       |                   |                           |                        |         |
|-----------------------------|-------------------|----------------------------|------------------------|---------|
| ICD                          | 175 (40.8)        | 113 (34.7)                 | 62 (60.2)              | <0.001  |

| Anti-arrhythmic drugs (n = 408) | Overall (n = 408) | Non-sustained VA (n = 326) | Sustained VA (n = 103) | P-value |
|---------------------------------|-------------------|----------------------------|------------------------|---------|
| Amiodarone                      | 23 (6.0)          | 16 (4.9)                   | 10 (9.8)               | 0.041   |
| Sotalol                         | 79 (18.4)         | 55 (16.9)                  | 24 (23.3)              |         |
| Propafenone/flecainide          | 15 (3.5)          | 9 (2.8)                    | 6 (5.8)                |         |
| β-blockers (n = 407)            | 206 (48.0)        | 156 (47.9)                 | 50 (48.5)              | 0.50    |

Variables are expressed as frequency (%), mean ± standard deviation, or median (interquartile range). Total number of patients with available data for a given variable are mentioned in parenthesis for variables with missing data. DSC2, desmocollin-2; DSG2, desmoglein-2; DSP, desmoplakin; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; JUP, junction plakoglobin; PKP2, plakophilin-2; PLN, phospholamban; PVC, premature ventricular complex; RVEF, right ventricular ejection fraction; TMEM43, transmembrane protein 43; TWI, T-wave inversion; VA, ventricular arrhythmia.
recent cardiac syncope (n = 5, 1.17%), NSVT (70 = 16.32%), PVC count (n = 105, 24.48%), extent of leads with TWI (n = 26, 6.06%) and RVEF (n = 19, 4.43%). From an initial cohort of 433 patients, four patients were excluded as >50% of their predictors were missing (four predictors or more).

Outcomes
During a median follow-up of [5.02 (2.05–7.90)] years, 103 patients (24%) experienced sustained VA events corresponding to an annual event rate of 4.98% [95% confidence interval (CI) 4.07–6.04]. Figure 1 shows the cumulative survival free from first sustained VA.

Among patients who experienced sustained VA during follow-up, the most common events were ICD treated VAs, which represented 59.2% of events (n = 61), followed by sustained VT (n = 32, 31.1%), SCA (n = 7, 6.8%), and SCD (n = 3, 2.9%). In patients with sustained or ICD treated VT events, the median cycle length (available in 57/93 events) was 280 ms (IQR: 246–315) which corresponds to 214 b.p.m. (190–243).

At last follow-up, 9 (2.1%) patients had died, including 2 from non-cardiac causes, and 7 (1.6%) had undergone heart transplantation.

External validation
Model validation revealed a Harrell C-index of 0.70 (95% CI 0.65–0.75). The calibration slope was 1.01 (95% CI 0.99–1.03) showing no significant difference in discrimination. The calibration of the model is graphically presented in Figure 2 demonstrating good overall agreement between predicted and observed shorter-term (1 year) and longer-term durations (5 year) with no significant over or under prediction across the complete risk spectrum. The distribution of patients according to their risk is presented in Supplementary material online, Figure S1 and calibration plots for intermediate durations (1, 2, 3, and 5 years) in Supplementary material online, Figure S2.

Two different aspects of the model fit or potential misspecification were evaluated. First, the assessment of individual predictor coefficients (Figure 3A) all showed no significant diversion from the original model in this cohort. This finding means that none of the individual coefficient would benefit from being modified from their original values to improve prediction in this cohort.

Second, the baseline survival function (i.e. predictors-adjusted survival) was assessed through the comparison of the baseline survival probabilities as a function of the predicted risk for each quintile of predicted risk in Figure 3B. The continuous line is the calibration hazard model, and the dotted line represents optimal calibration (i.e., perfect correspondence between predictions and observations across the risk spectrum). The calibration is shown to be acceptable across the risk spectrum with no significant under or over prediction in any risk category.
probabilities (i.e. predictors-adjusted survival) in the derivation and
the validation cohorts at different time points showing similar ex-
pected survival curves as shown numerically and visually in
Figure 3B and C. These findings suggest that the survival function
does not need to be modi-
fied to improve prediction in this cohort. Finally, the potential need to update the model was assessed by
comparing the fit of the published model with the derivation of a
new model in the validation cohort. The AIC of the published model
in the current cohort (1059.14) and of a model derived in this cohort
(1060.93) were not signi-
ficantly different (absolute difference in AIC of 1.79) indicating the absence of significant improvement in predic-
tions when fitting a model to this population.

As a sensitivity analysis, we repeated the process in patients with
complete data (n = 299) resulting in a similar C-statistic, calibration
slope, baseline risk, and calibration plot (see Supplementary
material online, Figure S3).

Clinical utility
We compared the performance of the risk calculator with published
consensus-based decision algorithms for ICD use in ARVC. As illu-
strated in Figure 4, the risk calculator generally had a superior net clin-
icial benefit when compared to the other published algorithms for
ICD use. Its performance becomes similar to the HRS consensus
above a risk of ~35%.

Finally, we graphically presented the impact of different threshold
for ICD implantation on the proportion of ICD use and the protec-
tion rate and compared to the published decision algorithms
(Figure 5). Higher thresholds result in less ICD use but less protection
from VA. As an example, a threshold of 15% would results in im-
planting 59.4% of patients with ICDs while protecting 85.7% of pa-
tients with incident VA events.

Subgroups analyses
The performance in subgroups of interest was visually explored by
calibration plots presented in Supplementary material online,
Figure S4. This cohort was not sufficiently powered to provide defi-
nite answers in these subgroups.

Calibration appeared acceptable in patients from both Europe and
North America, although this analysis had low precision in the North
American population due to its smaller size.

The model performed well both in probands and family members
with a possible trend toward overestimation in family members in
the lower risk spectrum. The calibration was also visually acceptable
both in PKP2 carriers and non-carriers.

Calibration plots according to the presence of an ICD show an ac-
ceptable agreement between predictions and observations with a
tendency towards overestimation in non-ICD carriers and under-
estimation in ICD carriers in the higher risk spectrum (see
Supplementary material online, Figure S5).

Discussion
In this study, we validated the published ARVC risk calculator in an
independent cohort of patients from 29 centres in 6 countries in
North America and Europe. Since its publication in 2019, the risk cal-
culator had a significant uptake in clinical practice. Ensuring its

Figure 3 Assessment of the model fit. Assessment of the individual predictors (A) show an absence of diversion from the initial model as all coeffi-
cients are non-significantly different from 0. Compared survival probability of the derivation and validation cohorts (B) and baseline survival hazard
(i.e. predictors-adjusted survival) presented as survival curves (C) both show similar expected survival. NSVT, non-sustained ventricular tachycardia;
PVC, premature ventricular complex; TWI, T-wave inversion; RVEF, right ventricular ejection fraction.
Comparison of the internal and external validation populations

While based on the same inclusion criteria (i.e. definite diagnosis of ARVC and no prior history of sustained VA at the time of diagnosis), the initial risk calculator included a high proportion of patients treated at highly specialized ARVC referral centres. Thus, a significant concern regarding this population is a possible selection bias due to the preferential referral of patients for advanced disease progression (i.e. recurrent VA referred for ablation and severe heart failure for advanced therapies). This could potentially hamper external validity. The present cohort derived from 29 different centres in 6 countries is thus likely to reflect a more diverse ARVC population. Expectedly, the annual event rate in this validation cohort (4.98%, 95% CI 4.07–6.04) was slightly lower, although non-significantly, than in the derivation population (5.6%, 95% CI 4.7–6.6) during a similar follow-up period [5.02 (2.05–7.90) years in the validation versus 4.83 (2.44–9.33) years in the derivation cohort]. This reflects the overall high risk of VA events in definite ARVC patients such as those included in this study which is consistent with prior literature and often preceding structural changes.4,19,25–28

Some differences between the two cohorts (shown in Supplementary material online, Table S4) might have limited the potential discrepancy in event rates, such as a higher proportion of probands (64.8% vs. 49.8%, P < 0.001) and males (54.8% vs. 44.7%, P = 0.002) in the current cohort. Conversely, patients in the present cohort were slightly older (43.1 vs. 38.2 years of age, P < 0.001), had less recent cardiac syncope and NSVT. The proportion of patients with decreased LVEF (<50%) was also higher in this cohort (17.7 vs. 12.7, P = 0.002). Although individuals in the current population were more likely to receive anti-arrhythmic drugs (P < 0.001) and β-blockers (48.0 vs. 37.9, P = 0.001), the proportion of ICD carriers at baseline was similar (41.1 vs. 40.8 P = 0.98). Finally, while still representing the predominant genotype, the proportion of patients with PKP2 causal variants was lower than in the derivation cohort (39.4% vs. 51.1% of tested patients) factoring that the current cohort has a lower proportion of patients with known genetic information. This predominance of PKP2 genotype is consistent with prior literature including patients with definite ARVC diagnosis.29 The proportion of patients with DSP causal variants was also higher (8.9% vs. 4.4%) than in the derivation cohort.

Model performance

The current validation cohort included 429 patients, of whom 103 had events. This met the minimally recommended sample size of 100 patients with and 100 patients without events to attain sufficient power for external validation.30 The initial study and internal validation using bootstrapping yielded an optimism corrected C-statistic of 0.77 (95% CI 0.73–0.81) and a calibration slope of 0.93 (95% CI 0.92–0.95). In the current study, we obtained comparable results with a slightly lower C-statistic of 0.70 (95% CI 0.65–0.75) showing acceptable discrimination and a calibration slope of 1.01 (95% CI 0.99–1.03) demonstrating almost perfect agreement between predictions and observations for sustained VA. As illustrated in the calibration plot, this concordance between observations and predictions was consistent across the risk spectrum.
Calibration in subgroups based on geographical origin, pedigree position, and genotype did not reveal major discrepancies although the study was not adequately powered to arrive at definitive conclusions in these subgroups.

The results of the current study are consistent with five small studies which have addressed the external validation of the ARVC risk calculator since its publication. The risk calculator was shown to perform well in patients with a definite diagnosis of ARVC\(^5,6,8\) and regardless of their exercise status.\(^7\) The validation study by Baudinaud et al.\(^6\), on a cohort of 115 patients, only 15 with VA events, of whom only one had an ICD at baseline, reported a C-statistic of 0.84 (CI 0.74–0.93) while reporting an overestimation of the risk in lower risk patients.

**Clinical utility**

The model generally showed a superior net clinical benefit when compared to a risk factor approach as recommended in the three published consensus documents.\(^2,18,22\) The model was similarly shown to outperform the ITFC and HRS consensus in two separate cohorts.\(^5,6\) These studies, however, suggested highly different thresholds for ICD implantation (10% and 37%), assuming an equal weight to unprotected VA and unnecessary ICDs. We did not present such an analysis as we do not propose that these adverse events are equivalent and rather preferred the use of the weighted analysis along with the graphical presentation of the clinical implications of the different threshold. The question of the threshold for ICD implantation is a legitimate concern when using the risk calculator.
Establishing a single perfect threshold is a delicate undertaking as every cut-off point comes with a trade-off between unnecessary ICDs with their potential complications versus the potential for unprotected SCA. The relative weight of these opposing undesirable events varies significantly from one individual to another. In the individualized decision-making process; however, a few points should be considered when reflecting on the threshold for ICD use. First, when tempted to use a similar threshold as suggested by the guidelines for the hypertrophic cardiomyopathy (HCM) risk calculator (i.e. ≥6% within 5 years),13,32 the breakdown of the type of events is relevant. In ARVC cohorts, including the current study and in the derivation cohort, most events were either ICD treated events or sustained VA, while most events in the cohort leading to the HCM risk calculator cohort were SCD or SCA.33 Although most clinicians agree that sustained or ICD treated VAs represent significant events, supported by guidelines,2,34 the exact number of treated VA events corresponding to a potential SCD is unknown in ARVC. Another important aspect to consider is that none of these studies are prospective evaluations of the role of ICDs in SCD prevention. Such an undertaking would not be feasible in contemporary high-risk ARVC populations. However, from such prior studies in the general cardiomyopathy population the one which established a benefit for primary prevention ICDs with the lowest annual risk of mortality, SCD-HeFT, had an annual risk of SCD of 3.5%.35 Finally, the cost of ICDs is rarely a significant determinant nowadays in countries where ICDs can be considered in primary prevention.36 Factoring the low number of ICDs needed to treat one VA event in ARVC, decreases in the cost of devices, the lifespan of modern ICDs reaching 10 years, and the potential number of quality-adjusted five years (QALY) saved in this young, usually otherwise healthy population (only five individuals had non-arrhythmic death during follow-up in this cohort), the common, although debated thresholds for a QALY between 50,000 and 100,000 USD37 remains far of reach. Conversely, the rate of short- and long-term complications of ICDs remain significant in ARVC patients (annual rate of complications of 4.2% and of inappropriate shocks of 3.9%),38 and although subcutaneous-ICDs have become an appealing alternative, there is no evidence of a lesser risk.39,40

Thus, in light of these different considerations, we do believe that the best use of the risk calculator is as a shared decision making tool balancing the opposing risks of SCD and ICD use. It appears reasonable that the predicted 5-year risk threshold for recommending an ICD would range from 5% to 25%, depending on the patient’s values and preferences, and the clinician’s judgement. We acknowledge that the threshold may change in the future with advances in non-invasive treatments and innovations in ICD technology which may lower risks associated with devices.

Future improvements in the model
While the model demonstrated a better performance compared to other published decision algorithms, it remains imperfect as illustrated by a C-statistic of 0.70. While it is unlikely that any risk stratification tool for SCD could predict the totality of these events, different elements could potentially improve prediction in the future. The addition of more refined parameters indicating left ventricular involvement, including late gadolinium enhancement were recently suggested.9 Genotype may also improve SCD risk prediction as recently proposed for patients with phospholamban associated disease.41 Finally, additional invasive parameters such as programmed ventricular stimulation42 might add additional accuracy in intermediate-risk cases. Moreover, the model is based on prediction of risk from the time of diagnosis of ARVC; a time-updated model for repeated risk prediction may have practical clinical utility.

Limitations
In this study, the majority of sustained VA outcomes are ICD treated events. While this fact is not possible to overcome in most modern ARVC populations and while most would agree that these still represent significant events, they do not directly represent the underlying risk of SCD. However, this is a limitation shared with most of previous studies in this field, including most of those used to elaborate prior consensus-based risk stratification algorithms. While underpowered for events, calibration plots by ICD carrier status show acceptable correlation between predictions and observations. This reflects both that ICDs are implanted in patients believed to be at higher risk (selection bias), but also increase the detection of some arrhythmia that might have gone undetected otherwise (information bias) (see Supplementary material online, Figure S4). While family members are well represented in the derivation cohort (50.2%), they are less prevalent in the current cohort (35.2%), and contribute to a lower proportion of events (21.1%). The calibration plot in this specific subgroup, although underpowered, suggests possible overestimation in the lower risk patients which should be taken in consideration when using the model.

Missing data also represent a limitation of this retrospective cohort. Although a complete case analysis reassuringly demonstrates similar results with regard to performance, missing data could influence the relative benefit of the model over consensus-based methods.

Finally, this validation only applies to patients who were well represented in the derivation and validation cohorts. The model should thus not be used in patients who do not meet definite ARVC diagnosis as per 2010 TFC such as those with left dominant forms and in patients with rare malignant genotypes such as TMEM43-p.S358L, of which only 10 patients were included in this cohort.

Conclusion
In this external validation study, we demonstrated that the published ARVC risk prediction model not only provides accurate prognostic information in patients with ARVC without a prior history of sustained VA at diagnosis, but also performs generally better than other published decision algorithms. These findings support its clinical use as a valuable tool for risk stratification enabling consistent and effective shared decision making for ICD implantation.

Supplementary material
Supplementary material is available at European Heart Journal online.
Acknowledgements
We thank the ARVC patients and families who have made this work possible.

Funding
P.J. is supported by the Daniel Bravo Foundation grant and Spanish Society of Cardiology Magda Heras mobility grant, A.G. by the Wilton W. Webster Fellow of Heart Rhythm Society, The Johns Hopkins ARVD/C Programme by the Leonie-Wild Foundation, Leyla Erkan Family Fund for ARVD Research, The Hugh Calkins, Marvin H. Weiner, and Jacqueline J. Bernstein Cardiac Arrhythmia Center, Dr. Francis P. Chiramonte Private Foundation, Dr. Satish, Rupol, and Robin Shah ARVD Fund at Johns Hopkins, Bogle Foundation, Campanella Family, Patrick J. Harrison Family, Peter French Memorial Foundation, and Wilmerding Endowments, H.K.J. by grants from Novo Nordisk Foundation, Denmark (NNF18OC0031258 and NNF20OC0065151), S.A.L. by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007, R.T. by the Canada Research Chairs programme, J.C.T. by the Philippa and Marvin Carseley Cardiology Research Chair. S.G.P. receives support from Ricerca Corrente funding scheme of the Italian Ministry of Health and Italian Ministry of Research and University Dipartimenti di Eccellenza 2018 to 2022 grant to the Molecular Medicine Department (University of Pavia).

Conflicts of interest: C.M.: honoraria from Abbott, I.O.: grants, consulting fees or honoraria from BSM, Cytokinetik, Shire, Genzyme, Amicus, Menarini International, Boston Scientific, and Tenaya. S.A.L.: grants from BMS/Pfizer, Boehringer Ingelheim, fitbit, IBM, and consulting fees from BMS/Pfizer, Invitae, and Blackstone, J.S.H.: research grants from Boston Scientific, Abbott, and Medtronic and is on Scientific Advisory Board for Boston Scientific, H.K.J.: research grant from Novo Nordisk foundation and honoraria from Abbott and Biosense Webster, H.C.: consultant for Medtronic Inc., Biosense Webster, Pfizer, and Abbott. He receives research support from Boston Scientific Corp. C.A.J. receives salary support from this grant and consulting fees from Pfizer, J. C.-T. consulting fees from BMS/Pfizer and Bayer.

References
1. Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation 2015; 132: 441–453.
2. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72: e91–e220.
3. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Caliskan H, Darieaux FFC et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2019; 16: e301–e372.
4. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019; 40: 1850–1858.
5. Aqaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Comparison of different prediction models for the indication of implanted cardioverter-defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy. ESC Heart Fail 2020; 7: 4080–4088.
6. Baudinoud P, Laredo M, Badenac N, Rouanet S, Wainer X, Duthoit G, et al. External validation of a prediction risk model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Can J Cardiol 2021; 37: 1263–1266.
7. Gasperetti A, Dello Russo A, Busana M, Dessalani M, Pizzamiglio F, Sagnier AM, et al. Novel risk calculator performance in athletes with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2020; 17: 1251–1259.
8. Casella M, Gasperetti A, Gaetano F, Busana M, Sommariva E, Catto V, et al. Long-term follow-up analysis of a highly characterized arrhythmogenic cardiomyopathy cohort with classical and non-classical phenotypes-a real-world assessment of a novel prediction model: does the subtype really matter. Europace 2020; 22: 797–805.
9. Agaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2020; 75: 2753–2765.
10. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med 2016; 35: 214–226.
11. Corrigendum to: A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2022; 43: 2712.
12. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015; 162: W1–W13.
13. Marcus FJ, McKenna WJ, Sherrill D, Basso C, Bauche B, Blumenke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J 2010; 31: 806–814.
14. Richards S, Aziz N, Bale S,ick D, Das S, Gaster-Foster, J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424.
15. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681–694.
16. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377–399.
17. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley and Sons, 1987.
18. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J 2015; 36: 3227–3237.
19. Bosman LP, Sammani S, James CA, Cadrin-Tourigny J, Calkins H, van Tintelen JP, et al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis. Heart Rhythm 2018; 15: 1097–1107.
20. Ogeron GM, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A, et al. Performance of the 2015 International Task Force Consensus Statement risk stratification algorithm for implantable cardioverter-defibrillator placement in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 2018; 11: e005593.
21. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013; 13: 33.
22. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Caliskan H, Darieaux FFC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019; 16: e301–e372.
23. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res 2019; 3: 18.
24. James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. Circ Genom Prec Med 2021; 4: e003273.
25. Bhonsale A, James CA, Cadrin-Tourigny J, Calkins H, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011; 58: 1485–1496.
26. Mazzanti A, Ng K, Faragi A, Maranghi R, Chiadoroli E, Orphanoudi N, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016; 68: 2540–2550.
27. Battipaglia I, Scalone G, Macchione A, Pinnaocchio G, Laurito M, Mili M, et al. Association of heart rate variability with arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Med 2015; 62: 408–412.
28. Santangeli P, Dello Russo A, Pieroni M, Casella M, Di Base L, Burkhardt JD, et al. Fragmented and delayed electrograms within fibrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: results from a prospective risk stratification study. Heart Rhythm 2012; 9: 1200–1206.
29. Groeneveld JA, Bhonsale A, James CA, te Riele AS, Dooyes D, Tichnell C, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet 2015; 8: 437–446.
30. Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol 2005; 58: 487–493.
Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 2014; **35**: 2733–2779.

32. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J* 2014; **35**: 2010–2020.

33. Cadrin-Tourigny J, Tadros R. Predicting sudden cardiac death in genetic heart disease. *Can J Cardiol* 2022; **38**: 479–490.

34. Priori SG, Blomstrom-Lundqvist C. European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. *Eur Heart J* 2015; **36**(41): 2757–2759.

35. Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, et al. Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT. *J Am Coll Cardiol* 2020; **76**: 405–415.

36. Smith T, Jordans L, Theuns DA, van Dessel PF, Wilde AA, Hunink MG. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. *Eur Heart J* 2013; **34**: 211–219.

37. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. *N Engl J Med* 2014; **371**: 796–797.

38. Nordkamp LR, O, Postema PG, Knops RE, van Dijk N, Limpons J, Wilde AA, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. *Heart Rhythm* 2016; **13**: 443–454.

39. Knops RE, Olde Nordkamp LRA, Dehoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. *N Engl J Med* 2020; **383**: 526–536.

40. Orgeron GM, Bhonsale A, Migliore F, James CA, Tichnell C, Murray B, et al. Subcutaneous implantable cardioverter-defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: a transatlantic experience. *J Am Heart Assoc* 2018; **7**: e008782.

41. Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. *Eur Heart J* 2021; **42**: 2842–2850.

42. McKenna WJ, Asaad NA, Jacoby DL. Prediction of ventricular arrhythmia and sudden death in arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J* 2019; **40**: 1859–1861.

43. Saguner AM, Medeiros-Domingo A, Schwyzer MA, On CJ, Haegeli LM, Wolber T, et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. *Am J Cardiol* 2013; **111**: 250–257.